MedTrace Logo

Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND)

NCT03508713 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2018-05-14

No results posted yet for this study

Summary

To focus on the real world treat-to-target rate of early rheumatoid arthritis patients who will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA.

To explore the factors which influence the treat-to-target outcome.

Conditions

Interventions

DRUG

disease modified antirheumatic drugs or biological agents

Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA

Sponsors & Collaborators

  • Southern Medical University, China

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Min Yang, doctor · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-13
Primary Completion
2022-07-01
Completion
2022-07-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03508713 on ClinicalTrials.gov